Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - enalapril maleate, quantity: 10 mg - tablet - excipient ingredients: sodium stearylfumarate; croscarmellose sodium; lactose monohydrate; maleic acid; hypromellose - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - enalapril maleate, quantity: 10 mg - tablet - excipient ingredients: croscarmellose sodium; lactose monohydrate; hypromellose; sodium stearylfumarate; maleic acid - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - enalapril maleate, quantity: 20 mg - tablet - excipient ingredients: sodium stearylfumarate; croscarmellose sodium; lactose monohydrate; maleic acid; hypromellose - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - enalapril maleate, quantity: 20 mg - tablet - excipient ingredients: maleic acid; hypromellose; lactose monohydrate; sodium stearylfumarate; croscarmellose sodium - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a) -

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - enalapril maleate, quantity: 10 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; magnesium stearate; maize starch; iron oxide red; pregelatinised maize starch; lactose monohydrate - hypertension: renitec is indicated in the treatment of: - all grades of essential hypertension; - renovascular hypertension. congestive heart failure: renitec is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that renitec be administered together with a diuretic. left ventricular dysfunction: all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - enalapril maleate, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; sodium bicarbonate; iron oxide yellow; iron oxide red; magnesium stearate; maize starch - hypertension: renitec is indicated in the treatment of: - all grades of essential hypertension; - renovascular hypertension. congestive heart failure: renitec is indicated for the treatment of all degrees of symptomatic heart failure.in such patients, it is recommended that renitec be administered together with a diuretic. left ventricular dysfunction: all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension vasotec is indicated for the treatment of hypertension. vasotec is effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of vasotec and thiazides are approximately additive. heart failure vasotec is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients vasotec improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), vasotec decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survi

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension vasotec is indicated for the treatment of hypertension. vasotec is effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of vasotec and thiazides are approximately additive. heart failure vasotec is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients vasotec improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), vasotec decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for d

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - hypertension vasotec is indicated for the treatment of hypertension. vasotec is effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. the blood pressure lowering effects of vasotec and thiazides are approximately additive. heart failure vasotec is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients vasotec improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). asymptomatic left ventricular dysfunction in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), vasotec decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survi